Evaluation Effect of Amikacin-Cefepime Combination Against Biofilm Formation In XDR-Pseudomonas.aeruginosa
DOI:
https://doi.org/10.46966/msjar.v4i4.162Keywords:
Biofilm , Laboratory diagnosis, Extensive druge resistanceAbstract
Background:
The intent of the research was to evaluate how the combination of amikacin and cefepim affected biofilm formation in ten clinical isolates of extensive druge resist pseudomonas aeruginosa A total of 295 clinical samples were obtained from patients suffering from burns, UTI , wounds, and CSF. Laboratory diagnosis is based on biochemical and morphological testing, and the VITEK-2 Compact system is used for confirmation. 53 Pseudomonas aeruginosa isolates from 295 samples were identified in the findings, representing 18% of the total samples . Susceptibility test showed that isolates had greater percentages of resistance to ceftazidime (72%)followed by cefepime (60%) , while has low resist to colstin (2%) . 35 isolates (66%) of Pseudomonas aeruginosa were detected as multi druge resist , ten (19%) bacterial isolates resist more than five classes of antibiotics which considered As extensive druge resistance (XDR) . All XDR pseudomonas .aeruginosa showing strong biofilm formation .Combinations of cefepime and amikacin are more effective than their individual at preventing P. aeruginosa from forming biofilms in an in vitro environment .
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Kawther Abd-Aladil Mousa, Ahmed Harbi Ibraheem
This work is licensed under a Creative Commons Attribution 4.0 International License.
In submitting the manuscript to the Medical Science Journal for Advance Research, the authors certify that:
- They are authorized by their co-authors to enter into these arrangements.
- The work described has not been formally published before, except in the form of an abstract or as part of a published lecture, review, thesis, or overlay journal.
- That it is not under consideration for publication elsewhere,
- The publication has been approved by the author(s) and by responsible authorities – tacitly or explicitly – of the institutes where the work has been carried out.
- They secure the right to reproduce any material that has already been published or copyrighted elsewhere.
- They agree to the following license and copyright agreement.
License and Copyright Agreement
Authors who publish with Medical Science Journal for Advance Research agree to the following terms:
- Authors retain copyright and grant the Medical Science Journal for Advance Research right of first publication with the work simultaneously licensed under Creative Commons Attribution License (CC BY 4.0) that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors can enter into separate, additional contractual arrangements for the non-exclusive distribution of the Medical Science Journal for Advance Research published version of the work (e.g., post it to an institutional repository or edit it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) before and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
